Roche Nurix Deal Advances BTK Program
Roche Nurix deal sets U.S. co-commercialization and outlines near-term clinical catalysts, with material deal economics that matter to biotech investors.
KEY TAKEAWAYS
- Nurix receives $700 million upfront and is eligible for up to $2.3 billion in milestone payments.
- Companies will co-develop and co-commercialize in the U.S.; Roche commercializes outside the U.S.
- Development costs split 60% Roche and 40% Nurix with U.S. profits and losses shared 50/50.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
The Roche Nurix deal announced June 8, 2026, will co-develop and co-commercialize an investigational oral BTK degrader, expanding a pivotal chronic lymphocytic leukemia (CLL) program into planned Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria.
Deal Terms and Economics
Nurix Therapeutics and Roche signed an exclusive global licensing and collaboration agreement for bexobrutideg (NX-5948), an investigational oral Bruton’s tyrosine kinase (BTK) degrader, the companies said. Nurix will receive $700 million upfront and is eligible for development, regulatory, and sales milestone payments totaling up to $2.3 billion.
The companies will co-develop and co-commercialize bexobrutideg in the U.S., while Roche will commercialize the drug outside the U.S. Nurix will receive tiered ex-U.S. royalties ranging from the low to high teens. Development costs will be split 60% to Roche and 40% to Nurix, with U.S. profits and losses shared equally. The agreement is subject to Hart-Scott-Rodino antitrust clearance and customary closing conditions.
Development and Clinical Timeline
The collaboration covers malignant hematology, immunology, and neurology. It builds on an ongoing pivotal CLL program, with label-enabling studies across B-cell malignancies and planned Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria.
Roche said it plans to initiate a Phase 3 clinical trial in second-line CLL in summer 2026, providing a near-term clinical milestone for the partnership. The upfront payment gives Nurix immediate funding while preserving milestone upside. The allocation of development costs, equal U.S. profit-and-loss sharing, and tiered ex-U.S. royalties define how revenue and risk will be divided between the companies.
